According to (the report/article), ...Text: "Published"According to Agência Brasil, the team that will work on the clinical study willRecruitment of five patients aged 18 to 72 years to receive polylaminine.At this moment, researchers will attempt to understand if theThe substance has greater benefits than any potential harm to the body.EffectivenessFrom the medication,In turn, it will be restricted to other development phases of the drug.
TheNational Sanitary Surveillance Agency(Anvisa) has authorized the participation ofpatients with complete spinal cord injury between T2 and T10 after suffering trauma within the previous 72 hours. These individuals should also have an indication forsurgical procedure for spinal cord decompression.
The patients who will participate in the study will be treated at the Clinical Hospital and the Mercy of Saint House,both inSão Paulo.The units will havetrained doctors for the direct application of the substance to the bone marrow.
After the application of polylaminine, these patients willRehabilitated at the Association for Assistance to Children with Disabilities(AACD), where researchers will monitor the participants for the following six months.
Polylaminin is produced from aSmall fragment of the placentaAccording to studies, it has been helpingNeuron RegenerationAnd with that, it restores communication between the brain and the body, and should be applied up to six days after the injury. Since 2018, at least five patients who suffered complete loss of motor function and sensitivity have been followed by the team.significant advancements.
The substance has been studied for over 20 years by the researcher.Journalistic text: Tatiana SampaioFrom UFRJ.
Follow the news that the mainstream media doesn't show!
Follow Sputnik Brasil and gain access to exclusive content on our channel atText: Telegram.
Since Sputnik is blocked in some countries, you can get it here.DownloadOur mobile app (only for Android).